Respiratory disease companies develop therapies, diagnostics and research technologies for conditions affecting the lungs and airways. Their work supports earlier detection, improved disease monitoring and the development of treatments for acute, chronic and inherited pulmonary disorders.
This category includes companies working on:
Browse 69 UK respiratory disease companies below.
Inhaled antifungal therapies for serious respiratory fungal infections
Pulmocide is a late-stage biopharmaceutical company developing inhaled medicines for life-threatening respiratory fungal infections. Its lead compound opelconazole is a triazole antifungal designed for inhaled delivery to maximise pulmonary drug concentration while minimising systemic exposure and drug interactions.…
Inhalation and nasal drug product development and manufacturing CDMO
Bespak is a contract development and manufacturing organisation specialising in inhaled and nasal drug delivery. It supports pharmaceutical companies from feasibility, formulation and analytical development through clinical supply to commercial-scale manufacturing and fill-finish of pressurised metered dose inhalers.…
GPCR-targeted small molecule drugs for rare and inflammatory disease
Trio Medicines is a small pharmaceutical company developing small molecule therapeutics targeting G-protein coupled receptors for diseases with unmet clinical need. Its pipeline includes gastrin/CCK2 receptor antagonists for gastric neuroendocrine tumours, a selective β2-adrenoceptor antagonist, and a formyl peptide…
Antibody therapies targeting severe autoimmune diseases
argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases. The company markets VYVGART (efgartigimod), the first approved FcRn blocker in the UK, indicated for generalised myasthenia gravis and chronic inflammatory…
Blood-based CIZ1B biomarker test for early-stage lung cancer detection
Cizzle Biotechnology is a UK-based diagnostics company developing a non-invasive blood test for the early detection of lung cancer. The company's CIZ1B biomarker test identifies a stable plasma biomarker highly correlated with early-stage disease, offering an alternative to imaging or biopsy procedures. Cizzle's test…
Global biopharmaceutical company developing therapies for serious diseases
AbbVie is a global research-based biopharmaceutical company focused on the discovery, development and commercialisation of medicines across immunology, oncology, neuroscience and aesthetics. Its portfolio includes treatments for autoimmune diseases, haematological cancers, neurological conditions and women's health.…
Antibody discovery biotech targeting GPCRs in inflammatory disease
DJS Antibodies is a biotechnology company developing monoclonal antibody therapeutics against G protein-coupled receptors and other previously intractable disease targets. Its proprietary antibody discovery platform enables the generation of first-in-class antibodies against transmembrane proteins that have…
AI-powered medical imaging software for stroke, oncology and lung disease
Brainomix is a UK software company specialising in AI-powered imaging biomarkers and Software as a Medical Device (SaMD) to support clinical decision-making in stroke, lung fibrosis, and cancer. Its platform provides clinicians with automated imaging analysis to guide treatment decisions in acute stroke care and is…
Immunotherapeutics targeting drug-resistant bacterial infections
Centauri Therapeutics is a clinical-stage immunotherapy company developing treatments for life-threatening infectious diseases using its proprietary platform. The technology uses synthetic bifunctional molecules that recruit and redirect naturally occurring anti-glycan antibodies to target pathogens, engaging both…
Engineered hybrid interferon therapeutics for viral and immune-mediated disease
ILC Therapeutics is a pre-clinical biotechnology company developing hybrid interferons, an engineered cytokine drug class combining favourable attributes of multiple naturally occurring interferon subtypes. The platform rationally designs novel candidates with reduced toxicity and pleiotropic activity across multiple…
Clinical-stage rare disease biotech acquiring deprioritised pharma assets
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Founded in 2015, its business model centres on acquiring clinical-stage programmes deprioritised by large pharmaceutical companies and advancing them through further development. Lead programmes include…
Small molecule drug discovery focused on fibrosis and oncology
Redx Pharma is a clinical-stage biotech developing novel small molecule therapeutics for fibrotic disease and cancer. Its pipeline is anchored by zelasudil, a selective ROCK2 inhibitor in clinical development for idiopathic pulmonary fibrosis and other fibrotic indications, and zamaporvint, a Porcupine inhibitor…
AI-driven target identification and drug discovery from omics data
Intelligent OMICS is a biotechnology company applying artificial intelligence and machine learning to drug discovery and diagnostics. Its proprietary platform analyses transcriptomic, genomic, and proteomic datasets to identify novel biological targets and disease drivers. The company offers fee-for-service target…
Precision bacteriocin antibiotics targeting drug-resistant Gram-negative pathogens
Glox Therapeutics is a Scottish biotech developing a pipeline of engineered protein bacteriocins as precision antibiotics against drug-resistant Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Spun out of the Universities of Glasgow and Oxford in 2023, the company…
Rapid diagnostic platforms for infectious disease and consumer testing
Sapphiros is a privately held diagnostics portfolio company backed by KKR and Neoenta. UK operations include Biocrucible, a molecular diagnostics company developing ultra-rapid isothermal nucleic acid amplification assays, and an Extreme Volume Manufacturing capability producing lateral flow diagnostic tests at…
Oncology drug discovery and IP licensing from rural Wales
Morvus Technology is a privately owned pharmaceutical company engaged in the discovery, development, and out-licensing of novel oncology drugs and platform technologies. The company's portfolio includes ProTide nucleoside chemistry, out-licensed to NuCana plc for clinical development; an inhaled anti-tumour agent for…
Preclinical DMPK, bioanalysis and toxicology CRO
Pharmidex is a UK contract research organisation providing preclinical drug discovery and development services across DMPK, bioanalysis, toxicology, histology and in vitro ADME. Operating under GLP and GCP accreditation from its Hatfield facility, the company supports programmes in oncology, CNS, respiratory and…
AI-driven combinatorial analytics platform for chronic disease biology
PrecisionLife is a computational biology company applying AI-driven combinatorial analytics to complex chronic diseases. Its platform identifies causal biological mechanisms and patient subgroups at a resolution not achievable by conventional genomic methods, enabling novel drug target discovery, patient…
Computationally designed broadly protective vaccines against pandemic viruses
DIOSynVax is a clinical-stage biotechnology company developing broadly protective vaccines using a computational antigen design platform. The company's technology applies protein structure modelling and immune optimisation to engineer synthetic vaccine antigen payloads targeting conserved regions of viruses, enabling…
Cocrystal drug repurposing for oncology supportive care and fibrosis
Nuformix is a pharmaceutical development company using proprietary cocrystal technology to repurpose existing drugs for unmet medical needs in fibrosis and oncology. By reengineering a drug's crystal form, the company improves properties such as dissolution and absorption, creating differentiated, patentable products…